SCOHIA PHARMA is a bioventure specializing in the development of innovative therapies for lifestyle-related diseases, including cardiovascular, metabolic, and renal conditions. The company has a robust pipeline that includes various clinical and preclinical programs targeting specific health issues. Notably, SCO-240, an SSTR5 antagonist, is being investigated for its potential to treat growth hormone-related disorders, while SCO-483 focuses on congenital adrenal hyperplasia and Cushing's syndrome. The company employs a strategic approach to drug discovery, emphasizing the selection of diverse mechanisms of action and the consideration of backup compounds to mitigate development risks.

The drug discovery process at SCOHIA PHARMA involves several key stages, starting with exploratory research to identify drug targets, followed by screening lead compounds based on their binding affinity and toxicity profiles. Once promising candidates are identified, they undergo optimization and preclinical studies to assess pharmacology, pharmacokinetics, and toxicity. The company is committed to advancing its research and development efforts, with a focus on innovative solutions for conditions such as diabetes, obesity, and various genetic disorders. Additionally, SCOHIA PHARMA actively seeks partnerships for the commercialization of its value-added pipeline projects, further enhancing its capacity to bring new therapies to market.

Japan

By delivering drugs to patients,
we contribute to the creation of a happy society!

SCOHIA PHARMA

Company Details